A Study of of MORAb-004 in Subjects With Solid Tumors

Solid Tumor Clinical Trial

Official title:

A Study of the Safety, Tolerability, and Pharmacokinetics of MORAb-004, a Humanized Monoclonal Antibody, in Subjects With Solid Tumors

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00847054
• Other study ID #: MORAb-004-001
• Status: Completed
• Phase: Phase 1
• First received: February 5, 2009
• Last updated: July 15, 2014
• Start date: March 2009
• Est. completion date: April 2014

Study information

• Verified date: July 2014
• Source: Morphotek
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine the safety of multiple intravenous infusions of MORAb-004.

Description:

MORAb-004 is a monoclonal antibody directed against endosialin, a cell surface glycoprotein, which is expressed on cells involved in tumor vasculature. Studies have found endosialin to play a key role in tumor growth and neovessel formation in numerous cancer types including (but not limited to) renal, breast, colon, pancreatic, lung, endometrial, ovarian, melanoma, sarcoma, and neuroectodermal tumors. Preclinical pharmacological studies have shown that MORAb-004 is a potentially useful anti-cancer agent. This clinical trial is being performed to determine the safety of MORAb-004 in subjects with solid tumors, as well as to establish serum pharmacokinetics of the antibody, and to assess tumor antigens that may serve as predictors of a response to MORAb-004. Study Part 2 was added to enroll subjects with specific histological diagnoses (colorectal cancer and soft tissue sarcoma) to further characterize the safety and tolerability of 5 dose levels of MORAb-004 previously tested during the dose escalation in Part 1.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 80
• Est. completion date: April 2014
• Est. primary completion date: April 2014
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Subjects =18 years of age.

• Subjects with any malignant solid tumor without intracranial involvement or metastases diagnosed by standard pathology criteria that has failed standard chemotherapy.

• Subject must have disease, as defined by RECIST or evaluable by clinical signs/symptoms (e.g., ascites, pleural effusion, or lesions of less than 2 cm) supported by biomarker, radiologic, or pathologic studies conducted within 4 weeks prior to study entry.

• Karnofsky performance status =70%.

• Female subjects of childbearing potential and all male subjects must consent to use a medically acceptable method of contraception throughout the study period and for 30 days after MORAb-004 administration. A barrier method of contraception must be included.

• Laboratory and clinical results within the 2 weeks prior to Study Day 1 as follows:

Absolute neutrophil count (ANC) =1.5 x 109/L; Platelet count =100 x 109/L; Hemoglobin =10 g/dL; Serum bilirubin =2.0 mg/dL; Aspartate transaminase (AST) =2.5 x ULN; or =5 x ULN if liver metastases are present; Alanine transaminase (ALT) =2.5 x ULN; or =5 x ULN if liver metastases are present; Serum creatinine =2.0 mg/dL; prothrombin time (PT) and aPTT within institutional limits of normal.

• Subject must be willing and able to provide written informed consent.

• In Part 2 (expansion cohorts) ONLY, subjects must have a histological diagnosis of either CRC or STS (and subtypes, excluding bone sarcomas).

Exclusion Criteria:

• Known central nervous system (CNS) tumor involvement or metastases.

• Evidence of other active malignancy.

• Clinically significant heart disease (e.g., congestive heart failure of New York Heart Association Class III or IV, angina not well controlled by medication, or myocardial infarction within 6 months).

• Electrocardiogram (ECG) demonstrating clinically significant arrhythmias (Note:

Subjects with chronic atrial arrhythmia, i.e., atrial fibrillation or paroxysmal SVT, are eligible).

• Presence of severe lung disease (In the absence of clinically apparent severe lung disease, no formal testing is necessary. In the presence of clinically severe lung disease, FEV1 must be >60% in order for the subject to be eligible.)

• Active serious systemic disease, including active bacterial or fungal infection.

• Chronic inflammatory disorder, e.g., inflammatory bowel disease, active vasculitis.

• Chemotherapy, biologic therapy, or immunotherapy within 3 weeks prior to enrollment.

• Breast-feeding, pregnant, or likely to become pregnant during the study.

• Active hepatitis or human immunodeficiency virus (HIV) infection.

• Subjects who have received a previous monoclonal antibody therapy and have evidence of an immune or allergic reaction, or previously documented human anti-human antibody (HAHA).

• Subjects with large ascites or pleural effusion (=500 cc) based on results of most recent CT scan).

• Chronic systemic anticoagulation therapy with warfarin or heparin

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Solid Tumor

Intervention

Drug:
• MORAb-004 (monoclonal antibody to TEM1)
Intravenous administration

Locations

Country	Name	City	State
United States	Johns Hopkins Sidney Kimmel Comprehensive Cancer Center	Baltimore	Maryland
United States	Memorial Sloan Kettering Cancer Center	New York	New York
United States	Fox Chase Cancer Center	Philadelphia	Pennsylvania

Sponsors (1)

Lead Sponsor	Collaborator
Morphotek

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To determine the safety of multiple intravenous infusions of MORAb-004	Safety is evaluated by clinical assessment, monitoring of adverse events, laboratory evaluations, ECG.	Weekly while receiving study drug	Yes
Secondary	To determine the maximum tolerated dose (MTD) of MORAb-004 (within the administered range)	Monitoring of adverse events, laboratory test results and ECG results.	Weekly	Yes
Secondary	To determine optimal biologic dose (OBD) of MORAb-004	Monitoring of adverse events, laboratory evaulations and ECG results.	Weekly	Yes
Secondary	To establish the serum pharmacokinetics of MORAb-004 using a validated assay	Serial serum PK evaluations.	Weekly	No
Secondary	To describe changes in the objective measurements of tumor size and biomarkers (if applicable)after treatment with MORAb-004	CT or MRI evaluations following every other 4-week cycle.	bimonthly	No
Secondary	To detect any antibody response (human anti-human antibodies [HAHA] to multiple intravenous infusions of MORAb-004	Biweekly serum collection for detection of HAHA during treatment.	Biweekly	Yes